Valuation : Guizhou Xinbang Pharmaceutical Co., Ltd.

Market Cap 5.75B 855M 736M 691M 631M 1.18B 81.31B 1.19B 8.19B 3.19B 41.23B 3.21B 3.14B 137B P/E 2024
91x
P/E 2025 50.8x
Enterprise Value 5.07B 754M 649M 609M 556M 1.05B 71.73B 1.05B 7.22B 2.81B 36.37B 2.83B 2.77B 120B EV / Sales 2024
1.39x
EV / Sales 2025 0.97x
Free-Float
53.97%
Yield 2024
1.32%
Yield 2025 2.8%
08-28 Guizhou Xinbang Pharmaceutical Co., Ltd. Proposes Interim Cash Dividend for the Year 2026 CI
08-27 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-13 Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025 Payable on 21 May 2026 CI
04-28 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-20 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-22 Guizhou Xinbang Pharmaceutical Co., Ltd.(XSEC:002390) dropped from FTSE All-World Index CI
25-10-28 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-18 Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Implementation of Interim Profit Distribution Plan as Cash Dividend (A Shares) for 2025, Payable on 26 September 2025 CI
25-09-01 Guizhou Xinbang Pharmaceutical Co., Ltd. Proposes Interim Cash Dividend for 2025 CI
25-08-29 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-05-08 Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2024 (A shares), Payable on 21 May 2025 CI
25-04-29 Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-15 Guizhou Xinbang Pharmaceutical Co., Ltd. Proposes Final Dividend for 2024 CI
1 day-4.42%
1 week-0.33%
Current month+1.34%
1 month+2.02%
6 months-8.73%
Current year-5.90%
1 week 2.96
Extreme 2.96
3.29
1 month 2.89
Extreme 2.89
3.29
Current year 2.54
Extreme 2.54
3.49
1 year 2.54
Extreme 2.54
4.15
3 years 2.54
Extreme 2.54
5
5 years 2.54
Extreme 2.54
9.74
10 years 2.54
Extreme 2.54
12
Manager TitleAgeSince
Chief Executive Officer 58 2016-08-04
Director of Finance/CFO 53 2015-05-11
Investor Relations Contact 57 -
Director TitleAgeSince
Director/Board Member 58 2014-05-19
Chairman 33 2022-05-05
Director/Board Member 47 2023-05-11
Date Insider Type Main position Quantity % Market Cap. Importance
1/2/24 Buy

Chairman

3,106,200 0.1697%
10/18/22 Buy 392,300 0.0258%
10/12/22 Buy 213,600 0.0140%
Change 5-day change 1-year change 3-year change Capi.($)
-4.42%-0.33%-16.53%-35.26% 855M
-1.52%-7.23%+57.90%+108.72% 1,031B
-0.82%-2.63%+50.05%+64.43% 641B
+0.37%-3.06%+21.87%+74.48% 453B
-1.64%-4.75%+35.59%+35.54% 349B
-0.39%-2.76%+21.39%+38.01% 290B
-1.19%-2.21%+1.53%+11.51% 252B
-0.59%-3.15%+49.83%+67.70% 232B
-1.05%-2.29%-19.91%-54.10% 201B
+0.45%-0.27%+29.84%+91.34% 181B
Average -1.08%-2.91%+23.16%+40.24% 363.06B
Weighted average by Cap. -0.88%-3.97%+36.81%+64.68%

Financials

2024 2025
Net sales 6.03B 897M 772M 725M 662M 1.24B 85.36B 1.25B 8.59B 3.34B 43.29B 3.37B 3.3B 143B 5.62B 836M 720M 676M 617M 1.16B 79.52B 1.17B 8.01B 3.12B 40.32B 3.14B 3.07B 134B
Net income 101M 15.08M 12.98M 12.19M 11.13M 20.9M 1.43B 21.05M 144M 56.2M 727M 56.61M 55.38M 2.41B 120M 17.89M 15.4M 14.46M 13.2M 24.8M 1.7B 24.98M 171M 66.68M 863M 67.17M 65.71M 2.86B
Net Debt -228M -33.9M -29.19M -27.41M -25.02M -47M -3.23B -47.34M -325M -126M -1.64B -127M -125M -5.42B -677M -101M -86.69M -81.4M -74.31M -140M -9.58B -141M -965M -375M -4.86B -378M -370M -16.09B
Logo Guizhou Xinbang Pharmaceutical Co., Ltd.
Guizhou Xinbang Pharmaceutical Co Ltd is a China-based company primarily engaged in the provision of healthcare services. The Company operates three main businesses. Healthcare services business primarily provides oncology and general healthcare services. Pharmaceutical distribution business primarily comprises hospital-based drug and device distribution, a retail network, and supply chain solutions. Pharmaceutical manufacturing business primarily produces traditional Chinese medicines, herbal slices, and comprehensive health products. The Company primarily operates within domestic market.
Employees
4,702
Date Price Change Volume
26-08-31 CN¥3.030 -4.42% 59,381,459
26-08-28 CN¥3.170 +2.26% 58,156,900
26-08-27 CN¥3.100 -.--% 25,319,199
26-08-26 CN¥3.100 -.--% 24,966,500
26-08-25 CN¥3.100 +3.33% 23,329,055

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 002390 Stock